Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

T, Vilsbøll; B, Brock; H, Perrild; K, Levin; HH, Lervang; K, Kølendorf; T, Krarup; O, Schmitz; M, Zdravkovic; T, Le-Thi; S, Madsbad

doi:10.1111/j.1464-5491.2007.02333.x

Public

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Shared by NobleBlocks on Jan 14, 2008 • 12:00 AM UTC

Authors:

Vilsbøll T

Brock B

Perrild H

Abstract

<h4>Aims</h4>To assess the effect of liraglutide, a once-daily human glucagon-like peptide-1 analogue on pancreatic B-cell function. methods: Patients with Type 2 diabetes (n = 39) were randomized to treatment with 0.65, 1.25 or 1.9 mg/day liraglutide or placebo for 14 weeks. First- and second-phase...

Discussions